The sale caps a difficult time for zilovertamab and ONCT-808 under Oncternal’s ownership. Zilovertamab was deprioritised by ...

AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous ...

The FDA has approved Takeda’s new immunoglobulin therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat ...

Proposals for drug exclusivities and feeble measures to combat drug shortages are unlikely to boost innovation, say some experts.

Vetter Pharma, has begun the construction of a new clinical manufacturing facility in Des Plaines, Illinois, US.

As the pharma sector braces for sector-specific tariffs from President Trump, what could the impact look like on supply ...

Torrent has signed definitive agreements to acquire stake in JB Pharma at an equity valuation of Rs256.89bn ($3bn) on a fully ...

The chronic kidney disease (CKD) anemia market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, ...

Price differences are especially pertinent with these weight loss drugs, which are officially called glucagon-like peptide-1 ...

While the UK continues its close 25-year partnership with Gavi, the US is halting funding to the organisation. In a move that ...

Porton Advanced Solutions and EVA Pharma have signed an MoU to enhance the development capabilities for CAR T-cell therapies.

Equipped with a new CEO, Vor Bio is transitioning into an autoimmune player, leaving cell and gene therapy behind.